Phase 3
Merck’s investigational pneumonia vaccine, V114, hit the mark in two Phase III studies, including one involving adult HIV patients.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
The TACTIC-E trial will investigate the safety and efficacy of experimental therapies designed to prevent and treat life-threatening complications associated with COVID-19 in hospitalized patients who are at early stages of the disease.
It was a busy week for clinical trial announcements. Here’s a look.
According to a BioPharma Dive report, since March, more than 100 biopharma companies announced their clinical trials were disrupted in some way because of the pandemic.
The company indicated the initial data was promising, but the data for overall survival benefit and additional secondary endpoints were not yet mature and the trial will continue.
Specifically, the product was examined for its use in subjects where pituitary surgery is not an option or has not be curative.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.
The company announced it planned to soon start enrolling an open-label, single-arm Phase II/III clinical trial of remdesivir in about 50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents.
PRESS RELEASES